ArticleFolia microbiologica2026
Biogenic synthesis of ZnO based nanobiotics using the extract of an endophytic bacteria Paenibacillus sp. strain IHC2 and evaluation of antibacterial and anti-nematicidal activities.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a serious health concern of the 21st century, affecting millions of people globally. The current study employed a novel microbe-mediated method for synthesizing ZnO-based nanobiotics to overcome AMR. An endophyte, Paenibacillus sp. strain IHC2, previously recovered from Indigofera heterantha root, was used as a source of green reductants and stabilizers to synthesize ZnO nanobiotics. These nanobiotics were then characterized using various spectroscopic methods, following which subjected to bioactivity evaluation against clinical drug-resistant bacterial pathogens and parasitic nematode, Caenorhabditis elegans. The UV-visible spectroscopy confirmed nanobiotic synthesis by showing a spectral peak at 395 nm. FTIR spectrum captured a range of organic functional groups (C–I, C–Br, C = C, C–O, C–H, O = C=O), from bacterial extract attached to the surface of the nanobiotics. The XRD analysis determined a spherical wurtzite morphology with a crystallite average size of 27.12 ± 7.16 nm. SEM images revealed polydispersed spherical nanobiotics and agglomerated morphologies with an average size of about 147.78 ± 34.71 nm. The EDX shows strong peaks at 1 eV and 8.7 eV for Zinc (65.53%) and a strong peak at 0.5 eV for Oxygen (7.08%). The antibacterial activities of the nanobiotic against clinical pathogens Staphylococcus aureus and Escherichia coli show zone of inhibition of 9.6 mm and 8.5 mm with an IC50 value of 4.08 and 5.66 mg/mL, respectively. The anti-nematodal activity of Paenibacillus sp. extract and ZnO nanobiotics against C. elegans shows an LD50 value of 113.35 ± 11.91 and 382.37 ± 5.40 µg/mL, respectively, after 24 h of exposure. Overall, we conclude that Paenibacillus sp. IHC2 extract mediated ZnO nanobiotics has moderate antibacterial and anti-nematicidal activities.
Indexed as
Identifiers
41945269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.